|
|
|
|
03/2002
|
M. G. Krukemeyer, L. Morawietz, C. Radke, M. Harren,
P. Neuhaus, V. Krenn Survival rates after liver transplantation have increased significantly in recent years as a result of advances in therapy and management of post-transplant complications. However, the development of chronic transplant rejection continues to be the leading cause of end-stage graft failure today. The pathogenesis of chronic liver transplant dysfunction is still poorly defined. cDNA microarray technology, a high throughput method, is used to profile complex inflammatory diseases in order to discover new disease-related genes. The exponentially growing amount of information concerning the human genome and gene expression and a growing global network of databases will change our view of inflammatory diseases, especially of acute and chronic transplant dysfunction. First experiments with cDNA array technology have demonstrated that in addition to a precise analysis a verification and a validation of array data are essential. For more functional interpretations of organ rejections in-vitro tests, animal models and validation with clinical data will provide further information. Bioinformatic structuring and development is needed for the huge amount of data. After an initial genome-wide screening the objective is to identify those genes which will allow a complete characterization of liver rejection, classification according to molecular pathophysiology including prognosis and prediction of the correct and most potent therapeutic regime. It is possible that pathogenetic relevant genes which have been identified by array technology could be targeted, which might become a feasible option for diagnosis and treatment of allograft rejection. Key words: liver transplantation, transplant
rejection, cDNA array, histopathology Prof. Dr. Veit Krenn |
|
|
|
| PABST SCIENCE
PUBLISHERS Lengerich, Berlin, Bremen, Riga, Rom, Viernheim, Wien, Zagreb |
|
